SCHEMBL280261

SCHEMBL280261

COc1cc(C)ccc1C(=O)N1CCC(NC(C)=O)C1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.53
HCRTR2 O43614 1/20 0.53
PDE2A O00408 3/20 0.50
MAP3K12 Q12852 2/20 0.48
GAA P10253 1/20 0.48
KDM5A P29375 3/20 0.46
GFER P55789 1/20 0.43
CCNK O75909 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
CDK7 P50613 1/20 0.43
CCNH P51946 1/20 0.43
MNAT1 P51948 1/20 0.43
CDK12 Q9NYV4 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
SMPD3 Q9NY59 2/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279857 0.81 KDM5A (0.47) KDM5AKDM5B
SCHEMBL12237808 0.79 HCRTR1 (0.52) HCRTR1HCRTR2PDE2AMAP3K12GAA
SCHEMBL279835 0.77 KMT2A (0.55) KDM5ACCNKCDK12KDM5B
SCHEMBL12948013 0.77 KMT2A (0.55) KDM5ACCNKCDK12KDM5B
SCHEMBL279836 0.76 EPHX2 (0.59) KDM5A
SCHEMBL12237798 0.76 L3MBTL3 (0.54) HCRTR1HCRTR2PDE2AKDM4E
SCHEMBL10293595 0.76 MEN1 (0.67) HCRTR1HCRTR2PDE2AMAP3K12GAA
SCHEMBL30230190 0.74 HTT (0.58) GAAKDM5AKDM4E
SCHEMBL280293 0.74 KDM5A (0.56) PDE2AKDM5AKDM5B
SCHEMBL8227080 0.73 SSTR5 (0.46) HCRTR1HCRTR2PDE2AMAP3K12GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HCRTR1 1025/4885HCRTR2 1086/4885PDE2A 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.